Ziff Brothers Investments L.l.c. Exits Position in Illumina (ILMN)

Illumina (ILMN) : Ziff Brothers Investments L.l.c. has sold out all of its stake in Illumina during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 223,695 shares of Illumina which is valued at $37,354,828.

Other Hedge Funds, Including , Opus Point Partners Management reduced its stake in ILMN by selling 914 shares or 4.04% in the most recent quarter. The Hedge Fund company now holds 21,729 shares of ILMN which is valued at $3,628,526. Illumina makes up approx 3.03% of Opus Point Partners Management’s portfolio. Thompson Davis sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 125 shares of ILMN which is valued $20,808. Herndon Capital Management added ILMN to its portfolio by purchasing 14 company shares during the most recent quarter which is valued at $2,329.Checchi Capital Advisers boosted its stake in ILMN in the latest quarter, The investment management firm added 22 additional shares and now holds a total of 958 shares of Illumina which is valued at $144,428. Illumina makes up approx 0.04% of Checchi Capital Advisers’s portfolio.

Illumina opened for trading at $168.72 and hit $169.0495 on the upside on Thursday, eventually ending the session at $168.56, with a gain of 0.13% or 0.22 points. The heightened volatility saw the trading volume jump to 5,62,774 shares. Company has a market cap of $24,711 M.

On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.

Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by CL King to ” Neutral” on Aug 22, 2016. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.